Retrieval of Patient Information After Discontinuation
- Registration Number
- NCT01658722
- Brief Summary
A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 169
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Observational Bapineuzumab Long term follow-up
- Primary Outcome Measures
Name Time Method Dependence Scale 4 years Caregiver's assessment of a patient's need for assistance
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term cognitive outcomes for Alzheimer's patients discontinuing bapineuzumab in NCT01658722?
How does bapineuzumab's amyloid-beta targeting mechanism compare to other monoclonal antibodies in Alzheimer's treatment?
What biomarkers were used to assess patient eligibility and response prediction in the NCT01658722 observational study?
What adverse events were reported in Janssen's bapineuzumab trials and how were they managed post-discontinuation?
How do bapineuzumab's effects in early-stage Alzheimer's compare to disease-modifying therapies like aducanumab?